Cloning antifungal single chain fragment variable antibodies by phage display and competitive panning elution.

Department of Biochemistry, Niigata University of Pharmacy and Applied Life Sciences, Japan.
Analytical Biochemistry (Impact Factor: 2.58). 09/2009; 395(1):16-24. DOI: 10.1016/j.ab.2009.08.003
Source: PubMed

ABSTRACT Phage display and two competitive panning elution conditions were used to isolate Candida-specific single chain fragment variable (scFv) antibodies. An scFv phage library constructed from splenic lymphocytes of mice immunized by idiotypic vaccination with an HM-1 killer toxin (HM-1)-neutralizing monoclonal antibody (nmAb-KT) was used for panning against Candidaalbicans membrane fraction (CaMF). Key steps were specific elution conditions to separately release the bound phages with original antigen HM-1+HM-1 peptide 6 and CaMF. The positive phages were screened by using enzyme-linked immunosorbent assay, and after nucleotide sequencing, clone expression, and purification, clone scFv-C1 was selected for detailed characterization. The scFv-C1 showed IC(50) values for cell growth against various Candida species and Saccharomyces cerevisiae as 2.40 to 6.40microM and 2.20microM, respectively. By using surface plasmon resonance analysis, the scFv-C1 had a K(d) value of 3.09x10(-11)M to nmAb-KT, indicating a 260-fold higher affinity than for HM-1. These results showed the generated scFv-C1 mimicking HM-1-binding affinity to nmAb-KT and in vitro antifungal activity. We believe that the effectiveness of the competitive panning elution method and antigen-specific recombinant scFv antibodies obtained in this study are excellent candidates for antimycotic drugs.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on anti-idiotypic network theory in light of the need for new antifungal drugs, we attempted to identify biologically active fragments from HM-1 yeast killer toxin and its anti-idiotypic antibody and to compare their potency as an antifungal agent. Thirteen overlapping peptides from HM-1 killer toxin and six peptides from its anti-idiotypic single-chain variable fragment (scFv) antibodies representing the complementarity determining regions were synthesized. The binding affinities of these peptides were investigated and measured by Dot blot and surface plasmon resonance analysis and finally their antifungal activities were investigated by inhibition of growth, colony forming unit assay. Peptide P6, containing the potential active site of HM-1 was highly capable of inhibiting the growth of Saccharomyces cerevisiae but was less effective on pathogenic fungi. However, peptide fragments derived from scFv antibody exerted remarkable inhibitory effect on the growth of pathogenic strains of Candida and Cryptococcus species in vitro. One scFv-derived decapeptide (SP6) was selected as the strongest killer peptide for its high binding affinity and antifungal abilities on both Candida and Cryptococcus species with IC(50) values from 2.33 × 10(-7) M to 36.0 × 10(-7) M. SP6 peptide activity was neutralized by laminarin, a β-1,3-glucan molecule, indicating this peptide derived from scFv anti-idiotypic antibody retains antifungal activity through interaction with cell wall β-glucan of their target fungal cells. Experimental evidence strongly suggested the possibility of development of anti-idiotypic scFv peptide-based antifungal agents which may lead to improve therapeutics for the management of varieties of fungal infections.
    Applied Microbiology and Biotechnology 06/2011; 92(6):1151-60. · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Phage display is a powerful technique in medical and health biotechnology. This technology has led to formation of antibody libraries and has provided techniques for fast and efficient search of these libraries. The phage display technique has been used in studying the protein-protein or protein-ligand interactions, constructing of the antibody and antibody fragments and improving the affinity of proteins to receptors. Recently phage display has been widely used to study immunization process, develop novel vaccines and investigate allergen-antibody interactions. This technology can provide new tools for protection against viral, fungal and bacterial infections. It may become a valuable tool in cancer therapies, abuse and allergies treatment. This review presents the recent advancements in diagnostic and therapeutic applications of phage display. In particular the applicability of this technology to study the immunization process, construction of new vaccines and development of safer and more efficient delivery strategies has been described.
    Human vaccines & immunotherapeutics. 12/2012; 8(12).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunoassay designs rely on the great specificity of antibodies and a suitable marker which facilitates the generation of a quantitative signal. Nowadays, there is no reliable method to measure the antibody titer of an anti-idiotypic antibody. We failed in our initial effort to measure the antibody titer of mouse anti-idiotypic antibody after idiotypic vaccination with the HM-1 killer toxin (HM-1) neutralizing monoclonal antibody (nmAb-KT). The injected antigen, nmAb-KT was a mouse immunoglobulin G (IgG); therefore the antibody titer measurement using a commercial antibody always gave a false positive signal against control mouse serum antibody in parallel with the antigen treated immunized serum antibodies. To get a reliable and clearly differentiable signal from enzyme-linked immunosorbent assay (ELISA), we labeled the idiotypic antigen with horseradish peroxidase (HRP) and used HRP-conjugated-nmAb-KT (nmAb-KT-HRP) to measure the antibody titer in the antigen treated mice, and the signal was found in high anti-nmAb-KT IgG response compared to the control mice, although the untreated control mouse had a significant amount of purified non-specific IgG. This method is amenable to long read lengths and will likely enable anti-idiotypic antibody titer measurement in a more specific and cost effective way without using any commercial antibody.
    Microbiology and Immunology 07/2014; · 1.55 Impact Factor


Available from
May 26, 2014